日本肝胆膵外科関连会议-大阪.pdfVIP

日本肝胆膵外科関連会議－大阪　プログラム ■ 合同開会式　5月13日(木)　8：15～8：30　第一会場 ■ 合同閉会式　5月14日(金)　17：10～17：20　第一会場 ■ 招待口演　5月13日(木)　13：00～14：00　第一会場(メインホール) 　　　“The Role of FDG-PET in the Management of Hepatic Tumors “ Steven M Strasberg , Pruett Professor of Surgery, Head Section of Hepatobiliary-Pancreatic Surgery, Washington University in Saint Louis, Saint Louis, USA. 　　司会：大柳治正 (近畿大学　外科) Abstract: The FDG-PET scanner was invented at Washington University in Saint Louis more than 20 years ago and in the past decade has found many uses for staging of cancer. In this presentation the physical and physiological basis for FDG-PET scanning will be described followed by analysis of its value in different hepatic and biliary tumors including colorectal hepatic metastases, hepatocellular cancer (HCC), cholangiocarcinoma and gallbladder cancer. Hepatic metastases from colorectal cancer have been treated surgically for over 20 years. The 5-year survival rate for colorectal hepatic metastases has remained at about 33% for 15 years In patients with colorectal hepatic metastases FDG-PET alters management in 25% of patients, but the effect on 5year survival has not been studied. Data in 100 consecutive patients will be reported that shows that staging using FDG-PET can raise the 5 year survival rate in resected patients to almost 60%. FDG-PET also creates a cohort of resectable patients in whom standard prognostic factors such as tumor number and size are no longer important and in which the dominant prognostic factor is the histologic grade of the primary tumor. The role of FDG-PET has also been studied in HCC. It is very useful in high grade HCC, but of less utility in low grade tumors. Results in cholangiocarcinoma and gallbladder cancer are promising. ■ サテライト国際シンポジウム　5 月12 日(水)　16 ：00～18 ：